Literature DB >> 3143561

Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy.

E B Menachem1, L I Persson, P J Schechter, K D Haegele, N Huebert, J Hardenberg, L Dahlgren, J P Mumford.   

Abstract

Vigabatrin, as a single oral dose of 50 mg/kg, was administered to 11 patients with drug-refractory complex partial epilepsy. Serial lumbar punctures were performed prior to and 5 times within the first week following treatment. Cerebrospinal fluid (CSF) concentrations of total GABA, free GABA, homocarnosine, homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and vigabatrin were determined as well as blood vigabatrin levels. CSF GABA, homocarnosine, HVA and 5-HIAA concentrations increased by 6 h after the single dose and remained elevated for up to 5-7 days. In contrast, CSF and blood vigabatrin levels were maximal within the first 24 h and were no longer detectable thereafter. Hence, these results are consistent with vigabatrin acting as an irreversible inhibitor of GABA-transaminase and suggest that it may also increase biogenic amine turnover.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143561     DOI: 10.1016/0920-1211(88)90025-3

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  16 in total

Review 1.  Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Authors:  P J Schechter; A Sjoerdsma
Journal:  Neurochem Res       Date:  1990-04       Impact factor: 3.996

2.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

3.  Vigabatrin's complicated journey--to be or not to be?

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

Review 4.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

5.  The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.

Authors:  E Ben-Menachem; L I Persson; P J Schechter; K D Haegele; N Huebert; J Hardenberg; L Dahlgren; J P Mumford
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  In Vivo Detection of CPP-115 Target Engagement in Human Brain.

Authors:  Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

Review 7.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

8.  Vigabatrin and psychosis.

Authors:  J W Sander; Y M Hart; M R Trimble; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

Review 9.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.